Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Sevelamer in diabetic nephropathy
IRCT20191111045401N1Phase 3Completed
- Sponsor
- Shahrekord University of Medical Sciences
- Start
- Jul 2019
- Modality
- Small Molecules, Biodegradable Polymers → Polymer-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in diabetic glomerulosclerosis comparing Sevelamer with Placebo (2 arms). Primary endpoints: hemoglobin A1c, erythrocyte sedimentation rate and 4 more. Started Jul 2019; status: completed.
02
Drugs
sevelamer carbonate
03
Conditions
diabetic glomerulosclerosis
Beyond the preview
Go deeper on IRCT20191111045401N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20191111045401N1.